Skin News and Research

RSS

New computational tool may aid surgeons plan for life-saving pediatric operation

A team of researchers at the University of California, San Diego and Stanford University has developed a way to simulate blood flow on the computer to optimize surgical designs. It is the basis of a new tool that may help surgeons plan for a life-saving operation called the "Fontan" surgery, which is performed on babies born with severe congenital heart defects.

24 Nov 2009

Vitamin D: A multi-purpose nutrient for overall health

A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."

24 Nov 2009

Horizon Health International, Exmovere Holdings enter into a marketing and distribution agreement

HORIZON HEALTH INTERNATIONAL CORP. is pleased to announce that it has executed a Definitive Agreement with Exmovere Holdings Inc. of McLean, Virginia USA (Exmovere). Under the terms of the Agreement Horizon will pay Exmovere a total of two million dollars over a one year period for the exclusive rights to market and distribute their products in Canada for a 15 year term.

23 Nov 2009

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.

23 Nov 2009

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

OEPA reports substantial reduction of river blindness in six endemic countries

A regional initiative launched in the 1990s to eliminate onchocerciasis (river blindness) in the Americas has substantially reduced the prevalence of the disease in recent years, as evidenced by a 31% decrease in the number of individuals requiring mass drug administration in six endemic countries. Results were reported today at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

23 Nov 2009

Children exposed to pollution and indoor allergens face increased risk of asthma

Children who are exposed to high levels of traffic-related pollution and high levels of indoor endotoxin early in life have six times the risk of developing persistent wheezing by age three than children exposed to low levels of traffic and indoor-related pollutants, according to new research from the University of Cincinnati College of Medicine.

23 Nov 2009

Gene deletion can increase common complication of bone marrow transplants

A commonly inherited gene deletion can increase the likelihood of immune complications following bone marrow transplantation, an international team of researchers reports in the November 22 advance online issue of Nature Genetics.

23 Nov 2009

Genes from same 'family' interact with each other to prevent skin cancer, says new study

CANCER RESEARCH UK scientists have shown, for the first time, how two genes from the same 'family' can interact with each other to stop cancer in its tracks - according to new findings published in Molecular Cell.

23 Nov 2009

Bacteria help in preventing inflammation after skin injury

On the skin's surface, bacteria are abundant, diverse and constant, but inflammation is undesirable. Research at the University of California, San Diego School of Medicine now shows that the normal bacteria living on the skin surface trigger a pathway that prevents excessive inflammation after injury.

22 Nov 2009

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

20 Nov 2009

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation.

20 Nov 2009

Image of a water flea wins top prize in the 2009 Olympus BioScapes Digital Imaging Competition

A glowing, eerily beautiful image of a water flea with its radiant green "crown of thorns" took top prize in the 2009 Olympus BioScapes Digital Imaging Competition®, the world's foremost forum for showcasing microscope photos and movies of life science subjects. Dr. Jan Michels, a zoologist at the University of Albrecht, Kiel, Germany, took top honors for the image of a water flea, with its defensive "crown of thorns" to protect it against predators. The image reveals not only the exoskeleton, but also interior detail down to the nuclei within its cells, seen as tiny, glowing blue dots. This

From Evident Corporation - Life Sciences 20 Nov 2009

I-STEM team succeeds in recreating a whole epidermis from hES cells

Stem cell research is making great strides. This is yet again illustrated by a study carried out by the I-STEM Institute (I-STEM/ Inserm UEVE U861/AFM), published in the Lancet on 21 November 2009. The I-STEM team, directed by Marc Peschanski has just succeeded in recreating a whole epidermis from human embryonic stem cells.

20 Nov 2009

U.S. Patent Office approves multiple patent claims from Helix BioMedix

Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company’s recent patent applications. US patent application 12/005653, “Short Bioactive Peptides for Cellular and Immunological Modulation,” covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.

20 Nov 2009

Data from second positive pivotal study of PSD502 for treatment of PE presented

At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

20 Nov 2009

New non-surgical procedure to improve body contours

The University of Alabama at Birmingham (UAB) Department of Dermatology is offering a new non-surgical, needle-free skin-tightening procedure that doctors say smoothes wrinkles, firms up baggy or loose skin and improves body contours.

19 Nov 2009

Low-level laser therapy increases tumour growth in skin cancer

High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Researchers writing in the open access journal BMC Cancer studied the pain relieving, anti-inflammatory 'cold laser', finding that it caused increased tumour growth in a mouse model of skin cancer.

19 Nov 2009

Positive results from Echo Therapeutics' Symphony tCGM System study

Echo Therapeutics, Inc., a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 Diabetes.

19 Nov 2009

Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE

At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

19 Nov 2009

Skin News and Research

New computational tool may aid surgeons plan for life-saving pediatric operation

Vitamin D: A multi-purpose nutrient for overall health

Horizon Health International, Exmovere Holdings enter into a marketing and distribution agreement

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Raptor Pharmaceutical announces results of NGX426 clinical trial

OEPA reports substantial reduction of river blindness in six endemic countries

Children exposed to pollution and indoor allergens face increased risk of asthma

Gene deletion can increase common complication of bone marrow transplants

Genes from same 'family' interact with each other to prevent skin cancer, says new study

Bacteria help in preventing inflammation after skin injury

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

Image of a water flea wins top prize in the 2009 Olympus BioScapes Digital Imaging Competition

I-STEM team succeeds in recreating a whole epidermis from hES cells

U.S. Patent Office approves multiple patent claims from Helix BioMedix

Data from second positive pivotal study of PSD502 for treatment of PE presented

New non-surgical procedure to improve body contours

Low-level laser therapy increases tumour growth in skin cancer

Positive results from Echo Therapeutics' Symphony tCGM System study

Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News